Literature DB >> 24018248

[The FRAX(®) tool in the prevention of fractures associated with androgenic deprivation therapy for prostate cancer].

Rafael Azagra1, Marta Zwart2, Juan Carlos Martín-Sánchez3, Amada Aguyé4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24018248     DOI： 10.1016/j.medcli.2013.06.008

Source DB:  PubMed          Journal:  Med Clin (Barc)        ISSN： 0025-7753            Impact factor:   1.725


× No keyword cloud information.
  3 in total

1.  [Prevalence of osteoporosis, estimation of probability of fracture and bone metabolism study in patients with newly diagnosed prostate cancer in the health area of Lugo].

Authors:  Jonatan Miguel-Carrera; Carlos García-Porrua; Francisco Javier de Toro Santos; Jose Antonio Picallo-Sánchez
Journal:  Aten Primaria       Date:  2017-06-17       Impact factor: 1.137

2.  [Osteoporosis and the FRIDEX model: When and how to make a pharmacological intervention in the primary prevention of fractures].

Authors:  Marta Zwart; Amada Aguyé; David Moriña; Rafael Azagra
Journal:  Aten Primaria       Date:  2017-01-04       Impact factor: 1.137

Review 3.  Pathophysiology of Bone Loss in Patients with Prostate Cancer Receiving Androgen-Deprivation Therapy and Lifestyle Modifications for the Management of Bone Health: A Comprehensive Review.

Authors:  Tae Jin Kim; Kyo Chul Koo
Journal:  Cancers (Basel)       Date:  2020-06-10       Impact factor: 6.639
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.